Meeder Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Meeder Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,942	Closed	-$6.47K	–	948
2024 Q4	$6.47K	Buy	+2,942	New	+$6.86K	﹤0.01%	787
2020 Q2	–	Sell	-580	Closed	-$18K	–	2167
2020 Q1	$18K	Buy	+580	New	+$30.6K	﹤0.01%	1280
2019 Q1	–	Sell	-98	Closed	-$5K	–	1741
2018 Q4	$5K	Buy	+98	New	+$4.72K	﹤0.01%	1405
2018 Q2	–	Sell	-404	Closed	-$30K	–	1592
2018 Q1	$30K	Buy	404 +33	+9%	+$2.42K	﹤0.01%	783
2017 Q4	$25K	Buy	371 +114	+44%	+$6.14K	﹤0.01%	869
2017 Q3	$13K	Buy	257 +158	+160%	+$7.62K	﹤0.01%	1011
2017 Q2	$5K	Sell	99 -15	-13%	-$552	﹤0.01%	1188
2017 Q1	$4K	Sell	114 -2,842	-96%	-$65.1K	﹤0.01%	1153
2016 Q4	$37K	Buy	+2,956	New	+$35.2K	﹤0.01%	591

Other funds holding ESPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PCM

PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Meeder Asset Management's ESPR Position: Q1 2025 in Review

Meeder Asset Management sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 2,942 shares — an estimated $6.47K sold.

Meeder Asset Management first reported a position in ESPR in Q4 2016 and held it in 9 quarters. The position peaked at $37K in Q4 2016. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

Meeder Asset Management reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
Meeder Asset Management sold 2,942 Esperion Therapeutics shares in Q1 2025, an estimated $6.47K.
Meeder Asset Management first reported a position in Esperion Therapeutics in Q4 2016 and held it in 9 quarters.
Meeder Asset Management's Esperion Therapeutics position peaked at $37K in Q4 2016.
186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Meeder Asset Management's 13F filing for Q1 2025, filed 7 May 2025.